Role of ERK1/2 kinase in cisplatin-induced apoptosis in human ovarian carcinoma cells.
- Author:
Shu-Qin WEI
1
;
Li-Hua SUI
;
Jian-Hua ZHENG
;
Guang-Mei ZHANG
;
Yan-Lin KAO
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; enzymology; pathology; Antineoplastic Agents; pharmacology; Apoptosis; drug effects; Cell Line, Tumor; Cell Survival; drug effects; Cisplatin; pharmacology; Enzyme Activation; drug effects; Female; Flavonoids; pharmacology; Humans; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; metabolism; Ovarian Neoplasms; enzymology; pathology; Signal Transduction
- From: Chinese Medical Sciences Journal 2004;19(2):125-129
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo investigate the role of extracellular regulated kinase (ERK1/2) pathway in cisplatin-induced apoptosis in human ovarian carcinoma cells.
METHODSCisplatin-induced apoptosis were stained with DAPI and was assessed microscopically in human epithelial adenocarcinoma ovarian cell line SKOV3 cells. ERK activation was determined by Western blotting using an anti-phospho-ERK antibody to detect ERK activity. The effect of PD98059 on ERK activity induced by cisplatin was detected by MTT assay.
RESULTSMarked apoptosis of SKOV3 cells resulted from 48 hours treatment with 20 microg/mL cisplatin. Strong activation of ERK was led to by 15 microg/mL cisplatin. Dose response and time course of cisplatin induced apoptosis in SKOV3 cells. Cisplatin-induced ERK activation occurred at 12 hours and increased to highest induction at 24 hours by Western blotting. The effect of PD 98059 on ERK activity induced by cisplatin at the concentration of 100 micromol/L PD 98059. Statistically significant decreased in cell survival were observed with 100 micromol/L PD 98059 at 15 and 20 microg/mL cisplatin (P < 0.05).
CONCLUSIONSCisplatin activates the ERK signaling pathway in ovarian cancer cell line SKOV3. Inhibition of ERK activity enhances sensitivity to cisplatin cytotoxity in ovarian cancer cell line SKOV3. Evaluation of ERK activity could be useful in predicting which ovarian cancer will response most favorably to cisplatin therapy.
